Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00786032
Other study ID # 567
Secondary ID
Status Completed
Phase N/A
First received November 4, 2008
Last updated January 6, 2015
Start date September 2011
Est. completion date August 2014

Study information

Verified date January 2015
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The goal of this VA demonstration project is to show that the Brain-computer interface (BCI) technology is a clinically practical and important new communication and control option that can improve the lives of veterans with amyotrophic lateral sclerosis (ALS). The project will test four well-supported hypotheses: (1) that people with ALS who find (or will soon find) conventional assistive technology inadequate can and will use a BCI system for important purposes in their daily lives without close technical oversight, 2) they will continue and even increase this use throughout the period of the study, (3) that BCI use will improve their lives, and 4) BCI will improve the lives of their families and caregivers.


Description:

People affected by severe motor disorders such as amyotrophic lateral sclerosis (ALS) need alternative methods for communication and control. They may not be able to use even the most basic conventional assistive technologies, which all rely in one way or another on muscles. For these people, communication and control technology that does not depend on neuromuscular function is essential. Brain-computer interfaces (BCIs) can give these individuals communication and control capacity that does not depend on nerves and muscles. It has been shown that even people who are almost completely paralyzed can control sensor motor rhythms and other features of scalp-recorded electroencephalographic (EEG) activity and that they can use this control to move a computer cursor in one or two dimensions, to select letters or icons, or even to move a robotic arm. The group is now focused on developing clinically practical BCI applications, translating them from the laboratory into people's homes, and establishing that they can have a positive impact on the lives of people with severe disabilities.

The goal of this VA demonstration project is to show that BCI technology is a clinically practical and important new communication and control option that can improve the lives of veterans with amyotrophic lateral sclerosis (ALS). The project will test four well-supported hypotheses: (1) that people with ALS who find (or will soon find) conventional assistive technology inadequate can and will use a BCI system for important purposes in their daily lives without close technical oversight, 2) they will continue and even increase this use throughout the period of the study, (3) that BCI use will improve their lives, and 4) BCI will improve the lives of their families and caregivers.

In accord with these hypotheses, the aims are:

Aim 1: To recruit 2-4 person teams of VA health professionals (e.g., physicians, nurses, nurse- practitioners, physician's assistants, EEG technicians, therapists, rehabilitation specialists, medical researchers) at each of 5-6 participating VA centers, and train them in the use and ongoing support of the BCI home system. These teams will use the VA ALS database, local ALS Association affiliates, and VA clinics to identify and recruit at each site 3-4 patients with ALS who are not adequately served by conventional assistive technology; have stable physical and social environments; and have caregivers with basic computer skills who are willing to support BCI use. The VA teams will set up BCI systems in the patients' homes and teach them and their caregivers how to use the system on a daily basis for applications that the individual patients desire, such as e-mail, environmental control, computer-mediated conversations, word-processing, and/or entertainment. The VA teams will provide long-distance Internet-based oversight as the patients begin to use BCI technology for communication and control in their daily lives. The Project teams will be available for onsite supervision at the beginning of BCI use and for periodic in-home evaluations later on. In addition to providing ongoing oversight and guidance of the project, the group will focus on reducing the need for continued expert support (both onsite and remote) by incorporating into the BCI software adaptations and adjustments that are essential for reliable operation and by further simplifying and streamlining the caregiver interface and other aspects of system operation. The ultimate goal is a practical system that can be used by many severely disabled people in their homes with minimal ongoing technical support.

Aim 2: To assess the extent and success of BCI usage and its impact on quality of life. Via the Internet link and periodic visits, the Project teams will quantify the amount of BCI usage in both absolute terms and in terms of its importance for supporting specific functions (e.g., interactions with family, e-mail); and will quantify BCI performance in terms of accuracy and speed. In addition, standard and specialized quality-of-life measures and BCI assessment questionnaires will be used to quantitatively evaluate the long-term impact of BCI technology on the lives of the users, their caregivers, and their families. The effects of disease progression (e.g., loss of remaining neuromuscular function) on the extent and nature of BCI use will also be monitored. We expect this work to establish that the communication and control applications provided by the BCI system are heavily used by people severely disabled by ALS, that the BCI can produce lasting improvement in their lives and in the lives of those close to them, and that the BCI can even allow people who would otherwise become totally locked-in to continue to interact with their families and friends.

The success of this project will depend on establishment and maintenance of reliable high-speed daily communication between the subjects, the VA sites, and the Project team. The VA and investigators must be able to evaluate each subject's EEG data every day, 7 days/week, so that questions can be answered, problems can be solved, and system parameters can be optimized within 24 hrs.

In this study, the first primary hypothesis is that the subjects will begin to use the BCI for important purposes in their daily lives and that they will continue and even increase this use throughout the period of the study. Thus, the primary quantitative outcomes for this hypothesis will be 1) the time spent using the BCI and 2) the change in this time over the study period. If their BCI use time is substantial and remains stable or increases over the study, we will be able to conclude that the subjects have found the BCI system desirable and valuable. The second primary hypothesis is that BCI will improve the quality of life of people severely disabled by ALS. Secondary outcomes include: caregiver quality of life measures; the patient and caregiver assessments of BCI usefulness; the BCI performance (i.e., speed and accuracy); and the amount of time spent by project staff in technical support.

The completion of this study and the achievement of its aims should help to move EEG based BCI technology out of the laboratory and to demonstrate that it is a powerful, clinically practical, and affordable communication and control technology that can substantially improve the lives of people with ALS. Furthermore, the study should validate and establish an important new option, BCI-based communication that the VA can provide to many of its most severely disabled patients. This achievement would make the VA the first and only entity in the world that can provide this radically new and important assistive technology to its patients.

Forty prospective BCI Users satisfied the inclusion criteria and provided informed consent*. [*Footnote 1: Two additional people who provided informed consent were subsequently found to not satisfy the inclusion criteria.] Thirty-seven completed the BCI assessment sessions, 28 satisfied the BCI accuracy criterion, and 27 had the BCI system placed in their homes.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date August 2014
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 79 Years
Eligibility Inclusion and Exclusion Criteria

1. Subject will be a veteran with El Escorial "Lab Supported Probable" or more definite diagnosis of ALS.

2. Subject will have lost the ability to communicate either verbally or in writing (item 1 or item 4 on the ALS Functional Rating Scale-Revised (ALSFRS-R) score of 0, Appendix A) .

3. Subject will be an adult (age >18).

4. Subject will be living at home.

5. Subject will be living within 100 miles of the participating study site.

6. Subject will have corrected visual acuity of at least 20/80.

7. Subject will have the ability to read and understand 6th grade English text on a computer screen.

8. Subject will be able to indicate willingness and understanding of the consent form (using their existing method of communication).

9. Subject will be able to identify one significant other.

10. Subject will identify one system operator (person that agrees to be trained and set up the BCI). This person can be the significant other.

11. Subject will be able to communicate non-verbally with their significant other, caregiver and system operator, and with study personnel.

12. Significant other, caregiver and system operator will be able to indicate willingness and understanding of the consent form, be adults (age> 18) and expect to be with the subject for at least one year.

13. Subject, significant other, caregiver and system operator will have life expectancy of at least one year.

14. In the opinion of the BCI installation team, the home environment is physically and technologically conducive to BCI operation and use.

15. Subject will demonstrate during the screening phase sufficient EEG interaction for the BCI to operate, i.e. classification rate of 70%. Classification rate is defined as the proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters.

16. Significant other, caregiver and system operator will demonstrate during the screening phase sufficient skill to manage the daily set-up and routine operations needed for the subject's basic operation of the BCI.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
BCI Device
A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.

Locations

Country Name City State
United States Albany VA Medical Center Samuel S. Stratton, Albany, NY Albany New York
United States VA Medical Center, Cleveland Cleveland Ohio
United States Durham VA Medical Center, Durham, NC Durham North Carolina
United States Providence VA Medical Center, Providence, RI Providence Rhode Island
United States VA Connecticut Healthcare System West Haven Campus, West Haven, CT West Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
VA Office of Research and Development New York State Department of Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BCI System Usage by the ALS Patient This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by total time. Up to 18 months No
Primary BCI System Usage by the ALS Patient This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by time per application. Up to 18 months No
Primary BCI System Usage by the ALS Patient This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by accuracy. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g., THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The independent-use periods of the 14 independent users was totaled by days. Of these days, BCI use was not possible for days (i.e. hiatus days) due to hospitalization, illness, home construction, travel, or BCI system assistant (SA) absence. Over these days, copy-spelling accuracy was averaged. Up to 18 months No
Primary BCI System Usage by the ALS Patient This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by selection rate. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g, THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The number of selections/min for the BCI applications was averaged across users. Up to 18 months No
Secondary BCI Usage by and Impact on the ALS Patient At three-month intervals, BCI use will be summarized. On a daily basis the BCI will record the total of number of selections made in copy spelling mode. Copy spelling mode is used for system calibration. Participants are expected to indicate that the burden associated with BCI use is inconsequential to the benefit derived from using the BCI. This will be assessed by the McGill Quality of Life (MQOL) at each visit. Up to 18 months No
Secondary Time of BCI Impact on the Significant Other and Systems Operator The quality of life of the significant other, caregiver and system operator will be measured using the Caregiver Burden Assessment at visits. At three month intervals, the significant other, caregiver and system operator will be asked to estimate how much time they spend on the following tasks per day in minutes: BCI System setup ( placing the electrode cap and initiating system operation), BCI System cleanup, and BCI System maintenance (removing cap). Up to 18 months No
Secondary Facility Support Speed of Solution This study will look at how the technical problems of the BCI are supported by the facility through analyzing the speed of solution. Up to 18 months No
See also
  Status Clinical Trial Phase
Terminated NCT02528071 - Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
Active, not recruiting NCT03604822 - Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS N/A
Completed NCT02891629 - Safety and Feasibility of the EyeControl Device N/A
Completed NCT02164253 - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Phase 2
Recruiting NCT03787420 - Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS. N/A
Recruiting NCT05663008 - Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Active, not recruiting NCT02286011 - Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis Phase 1
Recruiting NCT03330353 - Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy N/A
Active, not recruiting NCT03081338 - A Programme for Amyotrophic Lateral Sclerosis Care in Europe N/A
Active, not recruiting NCT03241784 - T-Regulatory Cells in Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04849065 - Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis Phase 2
Active, not recruiting NCT05276349 - Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
Completed NCT04090684 - Ciprofloxacin/Celecoxib Combination in Patients With ALS Phase 1
Active, not recruiting NCT04055623 - T-regulatory Cells in ALS Phase 2
Completed NCT02709330 - ALS Reversals - Lunasin Regimen Phase 2
Completed NCT03482050 - A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 1/Phase 2